Ionis Pharmaceuticals News

Earnings Preview: IONS to Report Financial Results on November 06

Moomoo NewsOct 31 21:00 ET

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

BenzingaOct 31 15:23 ET

Ionis Pharmaceuticals' (NASDAQ:IONS) Investors Will Be Pleased With Their 30% Return Over the Last Three Years

Yahoo FinanceOct 23 11:48 ET

Ionis to Hold Third Quarter 2024 Financial Results Webcast

PR NewswireOct 23 07:05 ET

Sector Update: Health Care Stocks Lean Lower Premarket Monday

MT NewswiresOct 21 09:15 ET

TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59

Moomoo NewsOct 21 07:31 ET · Ratings

Ionis Pharmaceuticals (IONS) Receives a Buy From TD Cowen

TipRanksOct 21 06:54 ET · Ratings

Ionis Pharmaceuticals Announces CHMP Recommends Approval for Wainzua

TipRanksOct 21 05:25 ET

Express News | Ionis And AstraZeneca's WAINZUA Recommended For EU Approval As First Self-Administered Treatment For HATTR-PN

BenzingaOct 21 02:53 ET

Express News | Wainzua (Eplontersen) Recommended for Approval in the EU by Chmp for the Treatment of Adults With Polyneuropathy Associated With Hereditary Transthyretin-Mediated Amyloidosis

ReutersOct 21 02:08 ET

Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $55

Moomoo NewsOct 11 08:31 ET · Ratings

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)

TipRanksOct 11 08:30 ET · Ratings

Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care

Seeking AlphaOct 10 14:37 ET

Guggenheim Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Raises Target Price to $65

Moomoo NewsOct 9 07:35 ET · Ratings

Express News | Ionis Pharmaceuticals Inc : Guggenheim Cuts Target Price to $65 From $70

ReutersOct 9 06:26 ET

Laidlaw Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $68

Moomoo NewsOct 8 20:31 ET · Ratings

Biogen Says Higher Dose of Nusinersen Shows Clinical Benefits in Spinal Muscular Atrophy

MT NewswiresOct 8 08:53 ET

Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy

Simply Wall StOct 5 09:53 ET

Express News | Ionis Pharmaceuticals Will Present New Three-year Data From The Phase 2 Open-label Extension Study As Well As Additional Results From The Pivotal Phase 3 OASIS and OASISplus Studies Of Donidalorsen For Hereditary Angioedema At The 2024 American...

BenzingaOct 3 07:05 ET

New Positive Donidalorsen Data to Be Presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

PR NewswireOct 3 07:00 ET